Monthly
US$200
Billed every month
Sign in to subscribeEperisone Hydrochloride Tablets
As of 13 November 2026, for Eperisone Hydrochloride Tablets, 8 applications are listed as under review at China's CDE; 7 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 12 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 3 applicationsSupplement delivery: 1 applicationNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders12View records ↓
Under-review filings8View records ↓
This year’s generic filers7View records ↓
NHSA approval numbers13View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 12 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 10 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Hunan Jiudian Pharmaceutical Co., Ltd | Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20266167 | 2026/09/29 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jewim Pharmaceutical (Shandong) Co., Ltd. | Jewim Pharmaceutical (Shandong) Co., Ltd. | 国药准字H20265310 | 2026/07/21 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20264821 | 2026/06/17 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Shanghai An Bi Sheng Pharmaceutical Technology Co., Ltd. romanized | Shou Guang Fu Kang Pharmaceutical Co., Ltd. romanized | 国药准字H20264075 | 2026/04/21 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | 国药准字H20256382 | 2025/12/22 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 2025/12/16 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Hunan Shang Zhong He Biopharmaceuticals Co., Ltd. romanized | Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20256045 | 2025/11/25 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Chengdu Shuo De Pharma Co., Ltd. romanized | Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20255554 | 2025/09/23 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Name not romanized | Wei Cai (Zhongguo) Pharma Co., Ltd. romanized | 国药准字H20133175 | 2013/10/10 | See source | Other drug | CDE |
| Shanghai Bo Yue Bio Technology Co., Ltd. romanized | Hua Yi Tai Kang Pharma Co., Ltd. romanized | 国药准字H20266119 | 2026/09/29 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Kang Pu Pharma Co., Ltd. romanized | Kang Pu Pharma Co., Ltd. romanized | 国药准字H20266278 | 2026/10/13 | 50mg | Generic approved under the new chemical-drug registration classification | CDE |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 2026/11/02 | 50mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 13 distinct approval numbers and 12 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | 国药准字H20256382 | 50mg | Category B | XM03BXY112A001010101504 | NHSA |
| Wei Cai (Zhongguo) Pharma Co., Ltd. romanized | 国药准字H20133175 | See source | Category B | XM03BXY112A001010101693 | NHSA |
| Guo Yao Group Yi Bin Pharmaceutical Co., Ltd. romanized | 国药准字H20040106 | 50mg | Category B | XM03BXY112A001010102294 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001010104028 | NHSA |
| Hunan Ya Da Pharmaceutical Co., Ltd. romanized | 国药准字H20020170 | 50mg | Category B | XM03BXY112A001010104994 | NHSA |
| Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20264821 | 50mg | Category B | XM03BXY112A001010180685 | NHSA |
| Shanghai An Bi Sheng Pharmaceutical Technology Co., Ltd. romanized | 国药准字H20264075 | 50mg | Category B | XM03BXY112A001010182990 | NHSA |
| Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20255554 | 50mg | Category B | XM03BXY112A001010183830 | NHSA |
| Hunan Shang Zhong He Biopharmaceuticals Co., Ltd. romanized | 国药准字H20256045 | 50mg | Category B | XM03BXY112A001010184674 | NHSA |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 50mg | Category B | XM03BXY112A001010185483 | NHSA |
| Guo Yao Group Yi Bin Pharmaceutical Co., Ltd. romanized | 国药准字H20040106 | 50mg | Category B | XM03BXY112A001010202294 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001010204028 | NHSA |
| Hunan Ya Da Pharmaceutical Co., Ltd. romanized | 国药准字H20020170 | 50mg | Category B | XM03BXY112A001010204994 | NHSA |
| Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | 国药准字H20264821 | 50mg | Category B | XM03BXY112A001010280685 | NHSA |
| Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20255554 | 50mg | Category B | XM03BXY112A001010283830 | NHSA |
| Hunan Shang Zhong He Biopharmaceuticals Co., Ltd. romanized | 国药准字H20256045 | 50mg | Category B | XM03BXY112A001010284674 | NHSA |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 50mg | Category B | XM03BXY112A001010285483 | NHSA |
| Guo Yao Group Yi Bin Pharmaceutical Co., Ltd. romanized | 国药准字H20040106 | 50mg | Category B | XM03BXY112A001010302294 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001010304028 | NHSA |
| Hunan Ya Da Pharmaceutical Co., Ltd. romanized | 国药准字H20020170 | 50mg | Category B | XM03BXY112A001010304994 | NHSA |
| Chengdu Shuo De Pharma Co., Ltd. romanized | 国药准字H20255554 | 50mg | Category B | XM03BXY112A001010383830 | NHSA |
| Hunan Shang Zhong He Biopharmaceuticals Co., Ltd. romanized | 国药准字H20256045 | 50mg | Category B | XM03BXY112A001010384674 | NHSA |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 50mg | Category B | XM03BXY112A001010385483 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001010404028 | NHSA |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 50mg | Category B | XM03BXY112A001010485483 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001010504028 | NHSA |
| Jiangsu Qian Ren Bio Technology Co., Ltd. romanized | 国药准字H20256268 | 50mg | Category B | XM03BXY112A001010585483 | NHSA |
| Wei Cai (Zhongguo) Pharma Co., Ltd. romanized | 国药准字H20041061 | 50mg | Category B | XM03BXY112A001020101693 | NHSA |
| Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | 国药准字H20010657 | 50mg | Category B | XM03BXY112A001020104028 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20266167 | 50mg | Category B | XM03BXY112A001010104942 | NHSA |
| Kang Pu Pharma Co., Ltd. romanized | 国药准字H20266278 | 50mg | Category B | XM03BXY112A001010105032 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 8 filings and 8 distinct first applicants.
Generic 8
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Suzhou Hong Sen Pharma Co., Ltd. romanized | CYHS2600240 | Generic | 2026/01/21 | Not stated by source | CDE |
| Heilongjiang Yi Da Hong Pharma Co., Ltd. romanized | CYHS2600699 | Generic | 2026/03/23 | Not stated by source | CDE |
| Yun Peng Pharmaceuticals Group Co., Ltd. romanized | CYHS2600666 | Generic | 2026/03/16 | Not stated by source | CDE |
| Changchun Lan Jiang Pharmaceuticals Technology Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanized | CYHS2600582 | Generic | 2026/02/28 | Not stated by source | CDE |
| An Shi Pharmaceutical (Zhong Shan) Co., Ltd. romanized | CYHS2600313 | Generic | 2026/01/30 | Not stated by source | CDE |
| Shanxi Tong Da Pharma Co., Ltd. romanized | CYHS2504270 | Generic | 2025/12/12 | Not stated by source | CDE |
| HUNAN WARRANT PHARMACEUTICAL CO.,LTD | CYHS2503092 | Generic | 2025/08/23 | Not stated by source | CDE |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2602801 | Generic | 2026/11/12 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 7 filings and 7 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Suzhou Hong Sen Pharma Co., Ltd. romanized | CYHS2600240 | Generic | 2026/01/21 | Not stated by source | CDE |
| Heilongjiang Yi Da Hong Pharma Co., Ltd. romanized | CYHS2600699 | Generic | 2026/03/23 | Not stated by source | CDE |
| Yun Peng Pharmaceuticals Group Co., Ltd. romanized | CYHS2600666 | Generic | 2026/03/16 | Not stated by source | CDE |
| Changchun Lan Jiang Pharmaceuticals Technology Co., Ltd. romanized; Zhi En Bio Technology Co., Ltd. romanized | CYHS2600582 | Generic | 2026/02/28 | Not stated by source | CDE |
| Beijing Zi Meng Pharmaceuticals Technology Co., Ltd. romanized; Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | CYHS2600494 | Generic | 2026/02/15 | Not stated by source | CDE |
| An Shi Pharmaceutical (Zhong Shan) Co., Ltd. romanized | CYHS2600313 | Generic | 2026/01/30 | Not stated by source | CDE |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2602801 | Generic | 2026/11/12 | Not stated by source | CDE |
API registrations
Non-component matches: 11 companies with A status and 8 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸乙哌立松 · No verified English name | Shandong Xin Shi Dai Pharma Co., Ltd. romanized | Y20260000569 | I | Exact ingredient | 2026/07/10 | CDE |
| 盐酸乙哌立松 · No verified English name | Hunan Fang Sheng Pharmaceutical Co., Ltd. romanized | Y20260000095 | I | Exact ingredient | 2026/02/26 | CDE |
| 盐酸乙哌立松 · No verified English name | Suzhou Hong Sen Pharma Co., Ltd. romanized | Y20250000745 | I | Exact ingredient | 2025/07/23 | CDE |
| 盐酸乙哌立松 · No verified English name | Hunan Hua Na Da Pharmaceutical Factory Shou Xing Drug Co., Ltd. romanized | Y20250000650 | I | Exact ingredient | 2025/07/22 | CDE |
| 盐酸乙哌立松 · No verified English name | Zhejiang Sai Mo Pharmaceutical Co., Ltd. romanized | Y20250000669 | I | Exact ingredient | 2025/07/17 | CDE |
| 盐酸乙哌立松 · No verified English name | Henan Dong Tai Pharmaceutical Co., Ltd. romanized | Y20250000369 | I | Exact ingredient | 2025/07/01 | CDE |
| 盐酸乙哌立松 · No verified English name | Zhi En Bio Technology Co., Ltd. romanized | Y20250000383 | I | Exact ingredient | 2025/05/08 | CDE |
| 盐酸乙哌立松 · No verified English name | Shandong Chen Long Pharma Co., Ltd. romanized | Y20250000304 | A | Exact ingredient | 2026/08/13 | CDE |
| 盐酸乙哌立松 · No verified English name | Hunan Jiu Dian Hong Yang Pharmaceutical Co., Ltd. romanized | Y20240001410 | A | Exact ingredient | 2026/07/01 | CDE |
| 盐酸乙哌立松 · No verified English name | Bai Yun Shandong Tai Shang Qiu Pharma Co., Ltd. romanized | Y20240001331 | I | Exact ingredient | 2024/12/02 | CDE |
| 盐酸乙哌立松 · No verified English name | Kang Pu Pharma Co., Ltd. romanized | Y20240000670 | A | Exact ingredient | 2026/01/08 | CDE |
| 盐酸乙哌立松 · No verified English name | Fujian Nan Fang Pharmaceutical Co., Ltd. romanized | Y20240000364 | A | Exact ingredient | 2025/12/17 | CDE |
| 盐酸乙哌立松 · No verified English name | Anhui Ding Wang Pharmaceuticals Co., Ltd. romanized | Y20240000605 | A | Exact ingredient | 2025/11/10 | CDE |
| 盐酸乙哌立松 · No verified English name | Sichuan Qing Mu Pharmaceutical Co., Ltd. romanized | Y20240000349 | A | Exact ingredient | 2025/07/25 | CDE |
| 盐酸乙哌立松 · No verified English name | Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | Y20230000997 | A | Exact ingredient | 2025/06/21 | CDE |
| 盐酸乙哌立松 · No verified English name | Guo Yao Group Yi Bin Pharmaceutical Co., Ltd. romanized | Y20190002612 | A | Exact ingredient | 2024/04/26 | CDE |
| 盐酸乙哌立松 · No verified English name | Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized | Y20190002225 | A | Exact ingredient | 2024/11/19 | CDE |
| 盐酸乙哌立松 · No verified English name | Hunan Ya Da Pharmaceutical Co., Ltd. romanized | Y20190001861 | A | Exact ingredient | 2025/02/15 | CDE |
| 盐酸乙哌立松 · No verified English name | Eisai Co., Ltd. | Y20170001587 | A | Exact ingredient | 2025/02/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/11/12Accepted
CISEN PHARMACEUTICAL CO., LTD.
CYHS2602801
Fact date: 2026/11/12 · Site observation date: 2026/11/13
View source ↗ -
2026/11/04No longer listed under review
Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized
CYHB2650102
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/04/28
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 7
NMPA · Table row 7 ↗ View source ↗ -
2026/11/02Supplement delivery
Qingdao Guo Hai Biopharmaceutical Co., Ltd. romanized
CYHB2650102
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 7 ↗ -
2026/10/30No longer listed under review
Xi Zhou Pharmaceuticals Technology (Zhejiang) Co., Ltd. romanized; Zhejiang Bei Sheng Pharma Han Sheng Pharmaceutical Co., Ltd. romanized
CYHS2501939
Fact date: 2026/10/30 · Site observation date: 2026/10/30
Accepted: 2025/05/30
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/28Notification delivery
Beijing Zi Meng Pharmaceuticals Technology Co., Ltd. romanized
CYHS2600494
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Site observation date: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 20 ↗ -
2026/10/24No longer listed under review
Hunan Qian Jin Xie Li Pharma Co., Ltd. romanized
CYHS2502029
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2025/06/09
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Eperisone Hydrochloride Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy